AIDS TREATMENT NEWS No. 051 - February 26, 1988
John S. James
The current chairman, retired admiral James D. Watkins, is very good at running this kind of commission, and has approached the task without preconceptions. Typical commissions write reports which mostly gather dust; the HIV commission has already implemented public-policy improvements even before its report is written.
Recently the Commission held three days of hearings on AIDS treatment development in New York, February 18-20; see our testimony above. Although these hearings were open to the public--as is everything this Commission does--surprisingly few people attended. The auditorium had seats for 700 people but only once was it even half full.
We cannot review the three days in this short space, but here are some impressions of the highlights.
The NIH (National Institutes of Health) scientists who testified looked almost entirely at long-term projects. The slogan of the day was that there is no quick fix. They asked for "bricks and mortar" -- more laboratory facilities -- as well as money to train more PhDs and postdoctoral researchers. They also asked for more independence for scientists to choose their own projects, instead of merely fulfilling preconceived research contracts as they have all too often had to do in the past. NIH wants more than year-to-year spending authority, so that administrators could make balanced long-term plans, and it wants permission to award grants faster to scientists.
We strongly support these requests to strengthen the often- neglected infrastructure of U.S. medical research. But we question the excessive control of old-boy networks and the resulting narrow focus on AZT-type drugs or long-term solutions only. This problem is less the fault of the scientists than of the pervasive lack of national mobilization to save the lives of those who are already ill. Scientists today depend so heavily on access to money, equipment, permissions, and prestige journals that they can only study what others approve. Even within their own fields they must follow national policy, seldom lead it.
The FDA (Food and Drug Administration) also wants more money, to be able to evaluate the greater numbers of AIDS drugs which increased research funding will produce. The FDA, like the NIH, usually insists on time frames too long to be useful to those now ill.
The Commission avoided asking pointed questions, and considerable self-congratulation, aggrandizement, and fluff crept into the testimony. There seems to have been a deliberate policy of keeping the witnesses comfortable so they could say more than if they had been on the defensive. The NIH, the FDA, and the alternative-treatment movement all got a good reception and left happy. Perhaps the Commission decided that there isn't time now to reform the agencies, that a better way to fight the epidemic is to mobilize existing forces by giving them what they need to operate.
880226
ATN05102
Copyright © 1988 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .